Astellas Shuts U.S./EU Phase III Trial But Resumes Asia Development For Differentiated Markets
This article was originally published in PharmAsia News
Astellas’ multi-track R&D approach leaves door open for a western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.
You may also be interested in...
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio
TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?